Intensity Therapeutics Inc. is developing what could become the first intratumoral chemotherapeutics to achieve better efficacy than systemic chemo by using a formulation technology that enables passive diffusion into tumor cells.

Early preclinical data show the formulations produce more complete responses and longer survival than IV chemo in models the company believes are both more robust and more representative of human pathology than those typically used.